Bioptik Technology (4161) — Cash Flow Reinvestment Rate
Bioptik Technology (4161) has a Cash Flow Reinvestment Rate of 0.09x as of December 2025, reinvesting NT$4.94 Million (capex NT$4.94 Million ) from operating cash flow of NT$53.21 Million. Check 4161 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Bioptik Technology Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Bioptik Technology across 8 annual periods. Explore 4161 debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Bioptik Technology (2017–2025)
Year-by-year capital reinvestment analysis for Bioptik Technology. For live market cap and broader valuation context, see Bioptik Technology market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.65x | NT$39.23 Million | NT$59.99 Million | NT$22.80 Million | ▲ +481.8% |
| 2024 | 0.11x | NT$17.85 Million | NT$158.82 Million | NT$15.51 Million | ▼ -61.1% |
| 2023 | 0.29x | NT$59.58 Million | NT$205.95 Million | NT$31.04 Million | ▼ -92.8% |
| 2022 | 4.02x | NT$221.24 Million | NT$55.06 Million | NT$17.08 Million | ▼ -80.0% |
| 2020 | 20.13x | NT$132.29 Million | NT$6.57 Million | NT$13.18 Million | ▲ +214.2% |
| 2019 | 6.40x | NT$262.81 Million | NT$41.03 Million | NT$27.42 Million | ▲ +77.1% |
| 2018 | 3.62x | NT$151.22 Million | NT$41.83 Million | NT$50.96 Million | ▼ -78.0% |
| 2017 | 16.46x | NT$181.43 Million | NT$11.02 Million | NT$62.72 Million | — |